Big Picture Bio成立，旨在识别、设计和优化有前景的癌症联合疗法-动脉网

Big Picture Bio founded to identify, design and optimise promising cancer combination therapies

D-Pharm 等信源发布 2026-09-21 14:45



可切换为仅中文







Big Picture Bio Ltd., has been founded to identify, design and optimise promising

Big Picture Bio Ltd. 的成立旨在识别、设计和优化具有前景的

cancer

癌症

combination therapies, using a generative world model to understand how tumours, immune cells and surrounding tissue interact across disease sites and patient subgroups. By combining AI-driven modelling with targeted wet lab validation, the Company aims to address one of oncology's most challenging .

组合疗法，利用生成式世界模型来理解肿瘤、免疫细胞和周围组织在不同疾病部位和患者亚组中的相互作用。通过将人工智能驱动的建模与靶向湿实验验证相结合，公司旨在解决肿瘤学领域最具挑战性的问题之一。

drug discovery

药物发现

problems – identifying combinations with a greater likelihood of working in patients.

问题——识别在患者中更可能有效的组合。

The Company has closed a £1.5 million (~$2 million USD) pre-seed funding round, co-led by Kadmos Capital and Exceptional Ventures with participation from Gloucester Ventures and angel investor John White. The pre-seed funding is in addition to £700,000 (~$950,000 USD) in non-dilutive funding received from Innovate UK through its Investor Partnerships Programme.

该公司已完成一轮150万英镑（约合200万美元）的预种子轮融资，由Kadmos Capital和Exceptional Ventures联合领投，Gloucester Ventures和天使投资人John White参与投资。此次预种子轮融资是在该公司通过英国创新署（Innovate UK）的投资者合作伙伴计划获得的70万英镑（约合95万美元）非稀释性资金之外的额外融资。

Together, the funding provides £2.2 million (~$3 million USD) to support Big Picture Bio as the Company takes its first designed drug combinations from in silico design into wet lab validation..

这笔资金共计220万英镑（约合300万美元），旨在支持Big Picture Bio公司将其首批经计算机设计的药物组合从硅基设计阶段推进至湿实验室验证阶段。

A key test of Big Picture Bio's combination-design approach is whether it can predict how treatments will perform in patients. The Company's platform has been validated against real-world clinical outcomes presented at ASCO, as well as correctly predicting the failure of Regeneron's recent fianlimab trial.

对Big Picture Bio公司组合设计方法的一项关键检验，在于其能否预测治疗方案在患者中的表现。该公司的平台已通过与在美国临床肿瘤学会（ASCO）上公布的真实世界临床结果进行验证，并准确预测了再生元公司近期fianlimab临床试验的失败。

Rather than positioning clinical prediction as the end product, Big Picture Bio uses this validation to test whether its models are identifying combinations with potential for clinical impact. The model reasons from the ground up, so its predictions are fully explainable and can be traced back to the underlying biology..

Big Picture Bio 并未将临床预测视为最终产物，而是利用这一验证过程来检验其模型是否识别出具有临床潜力的组合。该模型采用自下而上的推理方式，因此其预测结果完全可解释，并可追溯至基础生物学机制。

European startups at the forefront of the fight against cancer

站在抗癌斗争前沿的欧洲初创企业

With nearly 1,500 entities, Europe hosts a larger number of cancer-related startups than the US

欧洲拥有近1500家实体，其癌症相关初创企业的数量多于美国

Read news

阅读新闻

Big Picture Bio was founded by Dr Kerstin Papenfuss, CEO and co-founder, and Dr Mark Hammond, CTO and co-founder, bringing extensive experience across drug discovery, venture creation and AI-enabled scientific discovery. Kerstin previously served as Director of Pharma at Deep Science Ventures (DSV), where she founded 12 therapeutics and enabling-technology companies, while Mark co-founded DSV and led its engineering work in agentic scientific discovery.

Big Picture Bio 由首席执行官兼联合创始人 Kerstin Papenfuss 博士与首席技术官兼联合创始人 Mark Hammond 博士共同创立，他们带来了在药物发现、风险投资创建以及人工智能驱动的科学发现领域的丰富经验。Kerstin 此前曾在 Deep Science Ventures (DSV) 担任制药总监，期间创立了12家治疗技术和赋能技术公司；而 Mark 则联合创立了 DSV，并领导其在代理式科学发现方面的工程工作。

Together, they bring expertise spanning translational science, therapeutics and AI to Big Picture Bio's mission of designing cancer combination therapies..

他们共同将为 Big Picture Bio 的使命——设计癌症联合疗法——带来涵盖转化科学、治疗学和人工智能领域的专业知识。

The Company is supported by an advisory team with expertise in oncology, target validation, drug discovery, translational biology and commercial strategy. This includes Dr Laura Rosenberg, Director of Target Validation at AstraZeneca; Dr Duncan Young, Head of Search & Evaluation, Oncology Business Development & Licensing at AstraZeneca; Dr Garry Pairaudeau, CEO and co-founder of DaltonTx and former CTO of Exscientia; and Dr Christian Dillon, Chief Scientific Officer at PhoreMost..

公司由一支在肿瘤学、靶点验证、药物发现、转化生物学和商业战略方面拥有专业知识的顾问团队提供支持。团队成员包括：阿斯利康（AstraZeneca）靶点验证总监劳拉·罗森伯格（Laura Rosenberg）博士；阿斯利康肿瘤业务开发与许可部门搜索与评估负责人邓肯·杨（Duncan Young）博士；DaltonTx 首席执行官兼联合创始人、前 Exscientia 首席技术官加里·派罗多（Garry Pairaudeau）博士；以及 PhoreMost 首席科学官克里斯蒂安·迪伦（Christian Dillon）博士。

Dr Kerstin Papenfuss, CEO and co-founder, Big Picture Bio, said: “Cancer is not one disease driven by one target, but we still develop drugs as if it were. Combinations are how we beat it – and with more than 900 billion of them possible, no lab on earth can test its way to the right ones. That is the problem we built Big Picture Bio to solve: model the disease as the dynamic system it actually is, then design against it – combinations chosen because they are most likely to work in patients, not because they were the ones we could get to.

Big Picture Bio 的首席执行官兼联合创始人 Kerstin Papenfuss 博士表示：“癌症并非由单一靶点驱动的一种疾病，但我们仍然像对待单一疾病那样开发药物。联合疗法是我们战胜癌症的关键——然而，可能的组合超过 9000 亿种，地球上没有任何实验室能够通过实验逐一测试出正确的组合。这正是我们创立 Big Picture Bio 所要解决的问题：将癌症建模为其实际所处的动态系统，并据此进行药物设计——选择那些最有可能在患者身上奏效的联合疗法，而不是仅仅选择那些我们恰好能够实现的组合。”

This funding takes our first designed combinations out of the model and into the lab.”.

“这笔资金将我们首批设计的组合从模型阶段推进到实验室阶段。”

Dom Falcao, Founder of Deep Science Ventures added: 'For a decade, Mark and Kerstin have steered DSV through the creation of a slew of extremely exciting companies solving precisely these kinds of complex diseases, including Neobe, Cureage and Kindling, and almost every company they have built is on track to make it into the clinic.

Deep Science Ventures 创始人 Dom Falcao 补充道：“十年来，Mark 和 Kerstin 引领 DSV 创建了一系列极具前景的公司，专注于解决这类复杂疾病，包括 Neobe、Cureage 和 Kindling，而他们创立的几乎每一家公司都正稳步迈向临床应用阶段。”

Instilling that experience and expertise into a model that moves beyond the bleeding edge in AI to solve complex diseases at scale is a natural evolution of the methodology for building advanced therapeutics companies at DSV. It's been the greatest privilege of my career to build DSV alongside Mark and Kerstin and I am so glad DSV can be a part of the next phase of their journey.'.

将这种经验和专业知识注入到一个超越人工智能最前沿、能够大规模解决复杂疾病的模型中，是DSV构建先进疗法公司方法论的自然演进。能与Mark和Kerstin共同创立DSV，是我职业生涯中最大的荣幸，我也非常高兴DSV能成为他们下一段旅程的一部分。

Remy Kesrouani, Managing Partner, Kadmos Capital, said: “I had the privilege of working closely with Kerstin and Mark at the very beginning of Deep Science Ventures, and saw first-hand the determination, conviction and sheer resolve they bring to building ambitious, scalable businesses. Big Picture Bio is the culmination of that journey, applying a genuinely differentiated approach to AI to one of drug development’s hardest problems: predicting how complex clinical trials will actually behave.”.

Kadmos Capital 的管理合伙人 Remy Kesrouani 表示：“我有幸在 Deep Science Ventures 创立初期与 Kerstin 和 Mark 密切合作，亲眼见证了他们在打造雄心勃勃且可扩展的企业时所展现出的决心、信念和坚定意志。Big Picture Bio 是这一旅程的结晶，它将一种真正独具特色的 AI 方法应用于药物开发中最艰巨的难题之一：预测复杂临床试验的实际表现。”

Paolo Pio, Co-Founder and General Partner, Exceptional Ventures, commented: 'Big Picture Bio is going after a problem at the heart of modern oncology - how to identify the right combination therapies faster and with greater confidence. We believe the team has the scientific depth, technical ambition and commercial focus to build something genuinely important - a platform that can deliver value to partners today while laying the foundation for the next generation of cancer therapies.

Exceptional Ventures 的联合创始人兼普通合伙人 Paolo Pio 评论道：“Big Picture Bio 致力于解决现代肿瘤学的核心问题——如何更快、更有把握地确定正确的联合疗法。我们相信，该团队拥有深厚的科学底蕴、远大的技术抱负和明确的商业焦点，能够打造出真正重要的成果——一个既能当下为合作伙伴创造价值，又能为下一代癌症疗法奠定基础的平台。”

We are proud to co-lead the round along with Kadmos and support the company's next stage of growth.'.

我们很自豪能与 Kadmos 共同领投本轮融资，并支持公司下一阶段的成长。

https://www.bionity.com/en/news/1189866/big-picture-bio-founded-to-identify-design-and-optimise-promising-cancer-combination-therapies.html

QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery

QUANTRO Therapeutics 在转录组药物研发领域取得突破性进展

First successful simultaneous 10-target multiplex-screening

首次成功实现10靶标同步多重筛查

Read news

阅读新闻